Inspire Biotherapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Inspire Biotherapeutics's estimated annual revenue is currently $310k per year.
- Inspire Biotherapeutics's estimated revenue per employee is $77,500
Employee Data
- Inspire Biotherapeutics has 4 Employees.
- Inspire Biotherapeutics grew their employee count by 0% last year.
Inspire Biotherapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO & COO | Reveal Email/Phone |
2 | Chief Business Officer (Interim) | Reveal Email/Phone |
Inspire Biotherapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Inspire Biotherapeutics?
Inspire has developed a lung tropic AAV gene therapy platform that has demonstrated transduction and long-term expression in lung tissue without impact on other tissue types in disease-relevant animal models. We are currently pursing initiation of a Proof-of-Concept clinical trial for a lethal neonatal lung disease with short time to data readout and success of therapy. The platform can then be applied to Cystic Fibrosis and other monogenic lung diseases.
keywords:N/A
N/A
Total Funding
4
Number of Employees
$310k
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.7M | 4 | -20% | N/A |
#2 | $0.5M | 4 | -20% | N/A |
#3 | $0.5M | 4 | -20% | N/A |
#4 | $0.3M | 4 | N/A | N/A |
#5 | $0.3M | 4 | N/A | N/A |